But keep in mind the safe harbor clause (Safe Harbor provision of 35 U.S.C. § 271(e)(10)) allows any other company/lab to use your compound/process "in support of submissions to the FDA". This is taken very broadly in the field to mean if you are pre-commercial you can basically use anything you want, no one will sue you because if you're starting-up, everything can be claimed to support an eventual filing. Plus, if you have no revenue a patent fight has no value to the other party.
Obviously every marketed drug has IP around it preventing generics until the patents expire. A lot of inventions that lead to commercial products are actually derived from academic institutions. The Bayh–Dole Act did absolute wonders for the US in terms of biotech innovation. Pre-Bayh-Dole, any research using federal grant money had to go through a Byzantine process to determine IP ownership with a lot typically residing with the US federal government. Post-Bayh-Dole, it simply stayed with the inventor/inventing institution. Some people now consider this bad because evil drug companies are "privatizing the gains", but without that economic payout, they wouldn't have invested to bring the invention to market to begin with.
You could argue it moved the large biopharma companies to become development/networking/marketing companies, which is a fair point, but it simply moved the innovation to universities and nimble start-ups--which is better anyway for actual disruption and more equitably spreading economic gain.